Duke-Margolis Comments and Recommendations to House Ways and Means Committee Regarding Chronic Drug Shortages

Dear Chairman Smith, Ranking Member Neal, and members of the Committee,

The Duke-Margolis Institute for Health Policy appreciates the opportunity to provide comments and recommendations regarding the pressing issue of chronic drug shortages.

The Duke-Margolis Institute’s mission is to improve health, health equity, and the value of health care through practical, innovative, and evidence-based solutions. Duke-Margolis has conducted years of research and stakeholder engagement aimed at promoting drug supply chain reliability and preventing drug shortages, most recently including the work of the Duke-Margolis ReVAMP Drug Supply Chain Consortium that was founded in 2023. Through the Consortium, we’re working to generate effective policy solutions that promote a reliable drug supply chain to improve patient outcomes by reducing the frequency and severity of drug shortages.

The recommendations herein do not necessarily represent the views of Consortium Members and are not intended to limit the ability of Consortium members to provide their own comments on behalf of their independent organizations, but are informed by the Institute’s work with Consortium Members.

Read the full letter.